Liquid Biopsies in Follicular Thyroid Carcinomas-A Brief Report.
Marie-Louise Uhre HansenSimone Kloch BendtsenKathrine Kronberg JakobsenAne Yde SchmidtChristoffer Holst HahnChristian von BuchwaldChristian GrønhøjPublished in: Diagnostics (Basel, Switzerland) (2024)
Thyroid cancer (TC) represents a significant health burden globally, with follicular thyroid cancer (FTC) posing diagnostic challenges despite advancements. This pilot study aimed to evaluate the utility of a liquid biopsy with cell-free DNA (cfDNA) in patients with FTC. Blood samples were collected from 13 patients diagnosed with FTC, DNA extraction was performed, and cfDNA was analyzed using the Illumina's TruSight Oncology 500 High-Throughput panel. The results revealed low tumor mutational burden and minimal pathogenic variants in cfDNA, indicating challenges such as low DNA yield and poor material quality despite adequate coverage. Our findings indicate that cfDNA as an add-on diagnostic tool in patients with FTC might not be a useful supplement.
Keyphrases
- high throughput
- end stage renal disease
- circulating tumor
- cell free
- ejection fraction
- healthcare
- single molecule
- public health
- chronic kidney disease
- single cell
- palliative care
- ionic liquid
- ultrasound guided
- mental health
- prognostic factors
- copy number
- risk factors
- high grade
- nucleic acid
- patient reported outcomes
- quality improvement
- social media
- climate change
- human health
- health promotion